3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
73
Phase 3
19
Phase 1/2
14
Phase 1
13
Phase EARLY_PHASE1
1
Phase 4
1
Phase 2/3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Carcinoma, Non-Small-Cell Lung
7
Lung Neoplasms
5
Breast Neoplasms
5
Small Cell Lung Carcinoma
3
Thoracic Neoplasms
2
Ovarian Neoplasms
2
Neuroendocrine Tumors
2
Neoplasms
2
Lung Diseases
2
Carcinoma, Large Cell
2
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Retinoblastoma
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Non-small Cell Lung Cancer Metastatic
1
Non-Small Cell Lung Cancer Metastatic
1
Neoplasms, Second Primary
1
Neoplasms by Site
1
Nasopharyngeal Neoplasms
1
NSCLC
1
Medulloblastoma
1
Carcinoma, Squamous Cell
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Bronchogenic
1
Carcinoma
1
Cancer Therapy-related Cardiovascular Toxicity
1
Bronchial Neoplasms
1
Adenocarcinoma of Lung
1
Interventions
raltitrexed
1
pembrolizumab
1
methylnaltrexone
1
Specimen Handling
1
Radiotherapy, Intensity-Modulated
1
Radiosurgery
1
Paclitaxel
1
Immune Checkpoint Inhibitors
1
Docetaxel
1
Cisplatin
1
Carboplatin
1
Albumin-Bound Paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 4
×
Squamous Cell Carcinoma of Head and Neck
×
Carboplatin
×
Clear all
NCT04489888
2025-06-19
MK-3475-B10
Merck Sharp & Dohme LLC
Phase 4
Completed
101 enrolled
14 charts